The FDA is poised to review data from the DEVOTE trial, examining the rates of major adverse cardiovascular events in insulin degludec vs insulin glargine.
A common variant in the sulfonylurea receptor has been associated with a reduced risk of both type 2 diabetes and coronary heart disease.
There has been growing concern that testosterone replacement therapy is associated with adverse cardiovascular outcomes.
As achieved glycated hemoglobin A1c levels increased, the risk for a combined cardiovascular event increased.
Recent evidence clearly indicates that patients should be eating whole foods rather than attempting to get vitamins and antioxidants from dietary supplements.
Higher levels of free T4 were associated with atrial fibrillation, but TSH and total T3 were not.
Transgender men who are on long-term androgen therapy have higher levels of aortic stiffness, which may increase their risk for cardiovascular events.
Older patients with diabetes whose hemoglobin A1c levels were greater than 8% had an increased mortality risk.
A cohort study of primary care records in the United Kingdom did not find an increased risk of major cardiovascular events in patients with type 2 diabetes treated with insulin.
A stratification tool identifies risk factors in patients who may benefit from the addition of ezetimibe to their statin therapy.
Blood pressure trajectory monitoring can provide "an important approach" to identify those at high risk of developing hypertension and CVD, according to study investigators.
The American Heart Association releases a new statement suggesting that eating more earlier in the day may be healthier
Researchers set out to determine whether or not aspirin therapy in type 2 diabetes is effective.
Chronic stress identified as risk factor for cardiovascular disease.
Sitagliptin has a neutral effect on cardiovascular risk among older patients with type 2 diabetes.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Mid upper arm circumference is an independent predictor of survival in older adults with cardiovascular disease.
Postprandial hyperglycemia is linked to cardiovascular disease in patients with type 2 diabetes, regardless of HbA1c.
The US Preventive Services Task Force (USPSTF) recommends that certain adults aged 40 to 75 years without cardiovascular disease (CVD) history but with 1 or more cardiovascular (CV) risk factors initiate statins.
There is a graded association between intensity of statin therapy and mortality for patients with established atherosclerotic cardiovascular disease.
Calcium supplements, taken within recommended levels, can be considered safe for the heart, according to new guidelines and an evidence review published in the Annals of Internal Medicine.
Statins can interact with other drugs prescribed for cardiovascular disease, but there are ways to navigate the issue.
Study finds no significant difference in 10-year cardiovascular risk.
Young adults with long-standing, childhood-onset type 1 diabetes have increased total and cardiovascular disease mortality.
Treatments other than statins also can effectively reduce cardiovascular (CV) risk, according to a review and meta-analysis published in the JAMA.
Changes in quantity and attenuation of abdominal fat affect changes in incident CVD and metabolic risk factors.
Women who enter menopause before age 45 had a 50% greater risk for cardiovascular disease as well as an increased risk for cardiovascular death.
Findings suggest the long-term prognostic value of CCTA in asymptomatic type 2 diabetes.
Patients with type 2 diabetes have an elevated mortality risk, regardless of ischemic or nonischemic heart failure.
A historical analysis shows the Sugar Research Foundation may have influenced a review from Harvard researchers that downplayed the risks of sugar.
Endocrinology Advisor Articles
- Major Cardiovascular Event Incidence in T2D: Degludec vs Glargine
- Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
- Maternal Deaths in the United States: Sounding a Call to Action
- Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
- The Handoff: Your Week in Endocrinology News - 6/23/17
- Reduced Cardiovascular Events in Type 2 Diabetes Treated With Dapagliflozin
- Canagliflozin Reduces Cardiovascular Stress In Older Patients With Type 2 Diabetes
- Diabetic Retinopathy Caused by Sleep Apnea in T2D
- Transition-of-Care Algorithm Performs Well in Surgery Patients With Type 2 Diabetes
- GLP-1 Analog Counteracts Antipsychotic-Induced Glucose Intolerance, Weight Gain